Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 2/20 | 0.43 |
| ▸ | LTA4H | P09960 | 2/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 2/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | BAX | Q07812 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23453753 | 0.78 | SRD5A2 (0.54) | SRD5A2LTA4HFFAR1MGLLPTGDR2 | |
| SCHEMBL22609346 | 0.72 | ILK (0.52) | SRD5A2MGLLP2RX3 | |
| SCHEMBL23098203 | 0.69 | SRD5A2 (0.70) | SRD5A2LTA4HGRIN1GRIN2BFFAR1 | |
| SCHEMBL9906839 | 0.69 | SRD5A2 (0.70) | SRD5A2LTA4HGRIN1GRIN2BFFAR1 | |
| SCHEMBL10269397 | 0.67 | SRD5A2 (0.68) | SRD5A2LTA4HGRIN1GRIN2BFFAR1 | |
| SCHEMBL7178244 | 0.65 | LTA4H (0.67) | SRD5A2LTA4HGRIN1GRIN2BFFAR1 | |
| SCHEMBL246373 | 0.65 | LTA4H (0.67) | SRD5A2LTA4HGRIN1GRIN2BFFAR1 | |
| SCHEMBL24124580 | 0.63 | LTA4H (0.53) | SRD5A2LTA4HGRIN1GRIN2BIDH1 | |
| SCHEMBL10053900 | 0.63 | SRD5A2 (0.61) | SRD5A2LTA4HGRIN1GRIN2BFFAR1 | |
| SCHEMBL9563974 | 0.62 | CALM1 (0.41) | IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171503-A1 | GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF | ORFAN BIOTECH SL (ES) | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171503-A1 | GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF | PNPO, XDH, GLS | SRD5A2 679/4885LTA4H 369/4885GRIN1 1933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.